Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments

BACKGROUND: Some patients with neovascular age-related macular degeneration (nAMD) have persistent intraretinal/subretinal fluid (IRF/SRF) despite being treated with anti-VEGF agents. There is limited data on efficacy of switching to intravitreal brolucizumab (IVBr) in these patients. PURPOSE: To de...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Rehan M., Neal, Andrea, Yannuzzi, Nicolas A., Patel, Kevin H., Huo, Siya, Hariprasad, Seenu M., Bhatia, Sumit P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679013/
https://www.ncbi.nlm.nih.gov/pubmed/34926990
http://dx.doi.org/10.1177/25158414211055964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679013/
https://www.ncbi.nlm.nih.gov/pubmed/34926990
http://dx.doi.org/10.1177/25158414211055964

Ejemplares similares